drugset / Trial / NCT05831111
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Timeline
- Start
- 2023-04-05
- Primary completion
- 2026-10-07
- Completion
- 2026-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | mRNA-1189 | Vaccine | — | Intramuscular |
| Subject | mRNA-1195 | Vaccine | — | Intramuscular |
| Subject | mRNA-1195.1 | Unknown | — | Intramuscular |
| Subject | mRNA-1195.2 | Unknown | — | Intramuscular |